Under Connelly’s leadership, the U.S. division launched six new medicines last year, helping revenue grow 2.7% at the $11.3 billion unit, despite declining sales across GSK’s larger business. Connelly is now finalizing a complex deal with Novartis that will create a new consumer health care group and a bigger vaccine business. The deal will boost GSK’s revenue by some $2.1 billion.